Recordati licensed Ionis’ Alexander disease therapeutic candidate in a deal that shifts regulatory and commercial responsibilities to the Italian company. The arrangement supports Ionis’ strategy of regionalizing assets while capturing upfront value tied to commercialization rights outside the U.S. Separately, Ionis also secured $30 million upfront from Recordati for ex-U.S. rights to zilganersen, a near-approval rare disease antisense prospect. Together, the announcements underline Recordati’s continued appetite for rare-disease portfolios and Ionis’ focus on monetizing later-stage programs through licensing. For developers and investors, the key signal is how rare-disease companies are increasingly using regional rights and milestone-based structures to optimize balance sheets while accelerating global access paths.